AVIR Atea Pharmaceuticals

Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021

Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide a clinical and corporate update.

To access the live conference call, please dial (833) 301-1150 (domestic) or (914) 987-7391 (international) at least five minutes prior to the start time, and refer to conference ID 5795073. A live audio webcast of the call and accompanying slide presentation will be available in the Investors’ Events & Presentations section of the Company's website, . An archived webcast will be available on the Atea website approximately two hours after the event.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapeutics to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit .

Contacts

Jonae Barnes

SVP, Investor Relations and Corporate Communications

617-818-2985

Will O’Connor

Stern Investor Relations

212-362-1200



EN
05/08/2021

Underlying

AVIRAtea Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Atea Pharmaceuticals

 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and...

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV  Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration Regimen of Bemnifosbuvir/Ruzasvir has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect BOSTO...

August 7, 2025 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and...

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2025, and to provide a business update. ...

July 31, 2025 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3...

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US...

June 24, 2025 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and ...

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14, 2025, at 10:00 AM ET BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR...

May 12, 2025 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regi...

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025         Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When Co-Administered with Standard HIV Treatment Regimen Bemnifosbuvir Was Generally Safe and Well Tolerated with No Dose Adjustment Neededin Phase 1 Studies in Parti...

May 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch